Net Loss of Parmax Pharma reported to Rs 2.08 crore in the quarter ended September 2025 as against net loss of Rs 0.22 crore during the previous quarter ended September 2024. Sales declined 72.74% to Rs 2.53 crore in the quarter ended September 2025 as against Rs 9.28 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2.539.28 -73 OPM %-62.852.05 - PBDT-1.820.18 PL PBT-2.08-0.22 -845 NP-2.08-0.22 -845 Powered by Capital Market - Live News

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live News

Parmax Pharma announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live News

Net loss of Parmax Pharma reported to Rs 0.76 crore in the quarter ended June 2025 as against net profit of Rs 0.01 crore during the previous quarter ended June 2024. Sales declined 75.19% to Rs 1.94 crore in the quarter ended June 2025 as against Rs 7.82 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1.947.82 -75 OPM %-12.896.52 - PBDT-0.520.41 PL PBT-0.760.01 PL NP-0.760.01 PL Powered by Capital Market - Live News

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live News